Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G for Day One Biopharmaceuticals, Inc. Common Stock (DAWN).
- Disclosed ownership: 5.8%.
- Date of event: 30 Jun 2025.
BlackRock, Inc. - 30 Jun 2025 SCHEDULE 13G Report for Day One Biopharmaceuticals, Inc. Common Stock (DAWN)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- DAWN
- Shares outstanding
- 100,860,638 shares
- Disclosed Ownership
- 5,849,917 shares
- Ownership
- 5.8%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Jul 2025, 19:54:38 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 28 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 5.8% ownership in Day One Biopharmaceuticals, Inc. Common Stock (DAWN) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 28 Apr 2025.
- Current filing was accepted on 17 Jul 2025, 19:54.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.8% | 5,849,917 | 5,699,831 | 0 | Spencer Fleming | Managing Director |